Adrenergic control of lipid metabolism.
Adrenergic receptors are ubiquitous and mediate several important effects involving lipid metabolism. Thus, beta-adrenergic stimulation increases lipolysis and inhibits the activity of the lipoprotein lipase. In contrast, alpha-adrenergic stimulation inhibits fat cell lipid mobilisation. Unexpectedly, beta-adrenergic blockade increases plasma triglyceride levels and tends to lower the high density lipoprotein (HDL-cholesterol). These effects seem to be prevented or attenuated by concomitant alpha-blockade. Possible mechanisms for the adrenergic effect on lipid metabolism are reviewed.
D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002395:Catecholamines / Q000494:pharmacology; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL; D000242:Cyclic AMP / Q000378:metabolism; D005227:Fatty Acids / Q000378:metabolism; D006801:Humans; D050356:Lipid Metabolism; D008066:Lipolysis / Q000187:drug effects; D008071:Lipoprotein Lipase / Q000378:metabolism; D008075:Lipoproteins, HDL / Q000097:blood; D011224:Prazosin / Q000494:pharmacology; D051381:Rats; D011942:Receptors, Adrenergic, alpha / Q000502:physiology*; D011943:Receptors, Adrenergic, beta / Q000502:physiology*; D014280:Triglycerides / Q000378:metabolism
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D001786:Blood Glucose; D002395:Catecholamines; D008076:Cholesterol, HDL; D005227:Fatty Acids; D008075:Lipoproteins, HDL; D011942:Receptors, Adrenergic, alpha; D011943:Receptors, Adrenergic, beta; D014280:Triglycerides; D002784:Cholesterol; D000242:Cyclic AMP; D008071:Lipoprotein Lipase; D011224:Prazosin